GuidelineAnnals of the rheumatic diseases2017
2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.
Guideline in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.Annals of the rheumatic diseases · 2025Guideline
- The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.Pediatric rheumatology online journal · 2019Trial
- New treatments in myositis on the horizon.EULAR rheumatology open · 2026Review
- Update on clinimetric assessments in juvenile dermatomyositis: conceptual foundations, current tools, and future directions : (Narrative review describing the development, validation, and application of clinimetric outcome measures in juvenile dermatomyositis).Pediatric rheumatology online journal · 2026Review
- Sit to stand and timed up and go in idiopathic inflammatory myopathies.Scientific reports · 2025Observational
- Juvenile idiopathic inflammatory myopathies assessment by magnetic resonance imaging: a scoping review of protocols, scoring systems, and applications.Advances in rheumatology (London, England) · 2025Review
- Article
- [Advances in the diagnostics and treatment of juvenile dermatomyositis].Zeitschrift fur Rheumatologie · 2024Review
- Gene Expression Profiles of Treatment Response and Non-Response in Children With Juvenile Dermatomyositis.ACR open rheumatology · 2022Article
- Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis.Frontiers in pediatrics · 2022Article
- Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes.Rheumatic diseases clinics of North America · 2021Review
- Nailfold Capillaroscopy Abnormalities Correlate With Disease Activity in Adult Dermatomyositis.Frontiers in medicine · 2021Article
- Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies.Journal of Korean medical science · 2020Article
- A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome.Clinical rheumatology · 2020Article
- Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry.Pediatric rheumatology online journal · 2020Article
- Standardising measures in pediatric rheumatology: the experience of the international consensus dataset for juvenile dermatomyositis.Annals of translational medicine · 2018Article
- Update on outcome assessment in myositis.Nature reviews. Rheumatology · 2018Review
- Innovative Research Design to Meet the Challenges of Clinical Trials for Juvenile Dermatomyositis.Current rheumatology reports · 2018Review
- Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.Annals of the rheumatic diseases · 2018Article
- Current Classification and Management of Inflammatory Myopathies.Journal of neuromuscular diseases · 2018Review
Corrections and comments
- Erratum issuedCorrection:2018
Authors and funding
31 authors at 20 institutions in 11 countries.
Funding
Abstract
To develop response criteria for juvenile dermatomyositis (DM). We analysed the performance of 312 definitions that used core set measures from either the International Myositis Assessment and Clinical Studies Group (IMACS) or the Paediatric Rheumatology International Trials Organisation (PRINTO) and were derived from natural history data and a conjoint analysis survey. They were further validated using data from the PRINTO trial of prednisone alone compared to prednisone with methotrexate or cyclosporine and the Rituximab in Myositis (RIM) trial. At a consensus conference, experts considered 14 top candidate criteria based on their performance characteristics and clinical face validity, using nominal group technique. Consensus was reached for a conjoint analysis-based continuous model with a total improvement score of 0-100, using absolute per cent change in core set measures of minimal (≥30), moderate (≥45), and major (≥70) improvement. The same criteria were chosen for adult DM/polymyositis, with differing thresholds for improvement. The sensitivity and specificity were 89% and 91-98% for minimal improvement, 92-94% and 94-99% for moderate improvement, and 91-98% and 85-86% for major improvement, respectively, in juvenile DM patient cohorts using the IMACS and PRINTO core set measures. These criteria were validated in the PRINTO trial for differentiating between treatment arms for minimal and moderate improvement (p=0.009-0.057) and in the RIM trial for significantly differentiating the physician's rating for improvement (p<0.006). The response criteria for juvenile DM consisted of a conjoint analysis-based model using a continuous improvement score based on absolute per cent change in core set measures, with thresholds for minimal, moderate, and major improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.